Icecure Medical is trading 13.21% higher at $1.80 on September 30, 2026, with no clear catalyst identified. - No fresh company-specific announcement or clearly reported catalyst was found to explain the intraday rise. - China ProSense regulatory approval was announced September 10, making it prior news rather than a new event. - Major U.S. indices were higher, but healthcare was down; available reports do not tie the gain to broader market strength or establish another explanation.